{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:55:29Z","timestamp":1781528129329,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107137","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:32:23Z","timestamp":1773250343000},"page":"107137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effect of Dalfampridine on cognition, gait and fatigue in patients with multiple sclerosis: a randomized placebo-controlled study"],"prefix":"10.1016","volume":"109","author":[{"given":"Mai Mohamed Elsayed","family":"Abdeldayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Abdelnasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma Hamed","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Mohamed","family":"Abousteit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Mones","family":"Abushady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-5907","authenticated-orcid":false,"given":"Ali","family":"Shalash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107137_bib0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s41983-021-00383-4","article-title":"Assessment of cognitive functions in patients with multiple sclerosis","volume":"57","author":"Al-Falaki","year":"2011","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"key":"10.1016\/j.msard.2026.107137_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102305","article-title":"Normative values of the brief international cognitive assessment for multiple sclerosis (BICAMS) in an Arab population: corrected for age, sex and education","volume":"44","author":"Alboudi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107137_bib0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12991-017-0155-1","article-title":"An Arabic translation, reliability, and validation of patient health questionnaire in a Saudi sample","volume":"16","author":"AlHadi","year":"2017","journal-title":"Ann. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.msard.2026.107137_bib0004","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.clinthera.2015.10.014","article-title":"Effects of Dalfampridine extended-release tablets on 6-minute walk distance in patients with multiple sclerosis: a post Hoc analysis of a double-blind, placebo-controlled trial","volume":"37","author":"Applebee","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.msard.2026.107137_bib0005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2018.10.004","article-title":"Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: the IGNITE study","volume":"395","author":"Bakirtzis","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2026.107137_bib0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2377-12-55","article-title":"Brief international cognitive assessment for MS (BICAMS): international standards for validation","volume":"12","author":"Benedict","year":"2012","journal-title":"BMC Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2026.107137_bib0007","first-page":"S7","article-title":"Measuring balance in the elderly: validation of an instrument","volume":"83","author":"Berg","year":"1992","journal-title":"Can. J. Public Health"},{"issue":"14","key":"10.1016\/j.msard.2026.107137_bib0008","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1177\/1352458520912175","article-title":"Fatigue in multiple sclerosis: does the functional or structural damage prevail?","volume":"26","author":"Bertoli","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107137_bib0009","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7224\/1537-2073-13.1.4","article-title":"Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?","volume":"13","author":"Bethoux","year":"2011","journal-title":"Int. J. MS. Care"},{"issue":"3","key":"10.1016\/j.msard.2026.107137_bib0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7224\/1537-2073.2023-063","article-title":"Effects of physical therapy and dalfampridine on function and quality of life in nonambulatory individuals with multiple sclerosis: a randomized controlled trial","volume":"26","author":"Bromley","year":"2024","journal-title":"Int. J. MS Care"},{"issue":"3","key":"10.1016\/j.msard.2026.107137_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40271-014-0102-z","article-title":"Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program","volume":"8","author":"Crayton","year":"2015","journal-title":"Patient"},{"key":"10.1016\/j.msard.2026.107137_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105065","article-title":"The effect of disease modifying therapies on fatigue in multiple sclerosis","volume":"79","author":"Cruz Rivera","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.107137_bib0013","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a frontal assessment battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2026.107137_bib0014","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/03007995.2011.583229","article-title":"Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis","volume":"27","author":"Dunn","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.msard.2026.107137_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0317167100048691","article-title":"The impact of fatigue on patients with multiple sclerosis","volume":"21","author":"Fisk","year":"1994","journal-title":"Can. J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2026.107137_bib0016","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1191\/1352458502ms839oa","article-title":"Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters","volume":"8","author":"Flachenecker","year":"2002","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107137_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.expneurol.2013.05.016","article-title":"4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis","volume":"248","author":"Gobel","year":"2013","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107137_bib0018","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann. Neurol."},{"issue":"9665","key":"10.1016\/j.msard.2026.107137_bib0019","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2026.107137_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7224\/1537-2073.2013-023","article-title":"A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis","volume":"16","author":"Goodman","year":"2014","journal-title":"Int. J. MS Care"},{"issue":"11","key":"10.1016\/j.msard.2026.107137_bib0021","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1007\/s00415-020-10107-y","article-title":"A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications","volume":"268","author":"Hauer","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107137_bib0022","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107137_bib0023","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/1352458515581436","article-title":"Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial","volume":"22","author":"Hupperts","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107137_bib0024","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","article-title":"Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study","volume":"10","author":"Jensen","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2026.107137_bib0025","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1007\/s00415-015-7987-x","article-title":"Update on the pharmacotherapy of cerebellar and central vestibular disorders","volume":"263","author":"Kalla","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2026.107137_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101878","article-title":"Cross cultural adaptation and psychometric evaluation of an Arabic version of the modified fatigue impact scale in people with multiple sclerosis","volume":"39","author":"Khalil","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.107137_bib0027","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/1352458517694432","article-title":"New insights into the burden and costs of multiple sclerosis in Europe","volume":"23","author":"Kobelt","year":"2017","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107137_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.559","article-title":"Dalfampridine effects on cognition, fatigue, and dexterity","volume":"7","author":"Korsen","year":"2017","journal-title":"Brain Behav."},{"issue":"11","key":"10.1016\/j.msard.2026.107137_bib0029","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107137_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.neubiorev.2017.01.010","article-title":"Cognitive-motor dual-task interference: a systematic review of neural correlates","volume":"75","author":"Leone","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"5","key":"10.1016\/j.msard.2026.107137_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9050100","article-title":"Cognitive fatigue in multiple sclerosis: an objective approach to diagnosis and treatment by transcranial electrical stimulation","volume":"9","author":"Linnhoff","year":"2019","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.msard.2026.107137_bib0032","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/cts.13458","article-title":"Using an animal model to predict the effective human dose for oral multiple sclerosis drugs","volume":"16","author":"Liu","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"8","key":"10.1016\/j.msard.2026.107137_bib0033","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737175.2022.2106854","article-title":"Current perspectives on the diagnosis and management of fatigue in multiple sclerosis","volume":"22","author":"Marchesi","year":"2022","journal-title":"Expert Rev. Neurother."},{"issue":"4","key":"10.1016\/j.msard.2026.107137_bib0034","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13760-024-02508-x","article-title":"Dalfampridine in the treatment of primary fatigue in patients with multiple sclerosis: a randomized clinical trail","volume":"124","author":"Mavandadi","year":"2024","journal-title":"Acta Neurol. Belg."},{"issue":"8","key":"10.1016\/j.msard.2026.107137_bib0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.msard.2026.107137_bib0036","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107137_bib0037","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"issue":"7","key":"10.1016\/j.msard.2026.107137_bib0038","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/1545968310397204","article-title":"Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis","volume":"25","author":"Phan-Ba","year":"2011","journal-title":"Neurorehabilit. Neural Repair"},{"issue":"2","key":"10.1016\/j.msard.2026.107137_bib0039","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s13311-019-00813-5","article-title":"Dalfampridine to improve balance in multiple sclerosis: substudy from a randomized placebo-controlled trial","volume":"17","author":"Prosperini","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"17","key":"10.1016\/j.msard.2026.107137_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107137_bib0041","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1447-0594.2008.00509.x","article-title":"Montreal cognitive assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo","volume":"9","author":"Rahman","year":"2009","journal-title":"Geriatr. Gerontol. Int."},{"issue":"4","key":"10.1016\/j.msard.2026.107137_bib0042","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1152\/jn.1991.65.4.796","article-title":"Voltage-clamp analysis of the effects of classical conditioning on the hippocampus","volume":"65","author":"Sanchez-Andres","year":"1991","journal-title":"J. Neurophysiol."},{"issue":"1","key":"10.1016\/j.msard.2026.107137_bib0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1352458518815795","article-title":"Dalfampridine benefits ambulation but not cognition in multiple sclerosis","volume":"26","author":"Satchidanand","year":"2020","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2026.107137_bib0044","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14737175.2020.1801425","article-title":"Clinical assessment, management, and rehabilitation of walking impairment in MS: an expert review","volume":"20","author":"Soler","year":"2020","journal-title":"Expert Rev. Neurother"},{"issue":"10130","key":"10.1016\/j.msard.2026.107137_bib0045","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.msard.2026.107137_bib0046","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","article-title":"New perspectives in the natural history of multiple sclerosis","volume":"74","author":"Tremlett","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107137_bib0047","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WNF.0000000000000130","article-title":"Changes in cognitive processing speed, mood, and fatigue in an observational study of persons with multiple sclerosis treated with dalfampridine-ER","volume":"39","author":"Triche","year":"2016","journal-title":"Clin. Neuropharmacol."},{"issue":"14","key":"10.1016\/j.msard.2026.107137_bib0048","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.msard.2026.107137_bib0049","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/1352458515622695","article-title":"Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern","volume":"22","author":"Zorner","year":"2016","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:21:39Z","timestamp":1781526099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":49,"alternative-id":["S2211034826001732"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107137","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Dalfampridine on cognition, gait and fatigue in patients with multiple sclerosis: a randomized placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107137"}}